<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DA82066A-2B1B-412F-8D72-43273A319CA6"><gtr:id>DA82066A-2B1B-412F-8D72-43273A319CA6</gtr:id><gtr:name>Roche</gtr:name><gtr:address><gtr:line1>PRG Building 93 room 6 10</gtr:line1><gtr:line2>F Hoffman La Roche</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DA82066A-2B1B-412F-8D72-43273A319CA6"><gtr:id>DA82066A-2B1B-412F-8D72-43273A319CA6</gtr:id><gtr:name>Roche</gtr:name><gtr:address><gtr:line1>PRG Building 93 room 6 10</gtr:line1><gtr:line2>F Hoffman La Roche</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F31D4947-708C-4E72-8A87-651B54C39C8B"><gtr:id>F31D4947-708C-4E72-8A87-651B54C39C8B</gtr:id><gtr:firstName>Majlinda</gtr:firstName><gtr:surname>Lako</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E041E319-E561-4A17-916C-DCF2EC196DD9"><gtr:id>E041E319-E561-4A17-916C-DCF2EC196DD9</gtr:id><gtr:firstName>Lyle</gtr:firstName><gtr:surname>Armstrong</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FI02333X%2F1"><gtr:id>C174C074-FAB8-4132-91F4-46C01997D147</gtr:id><gtr:title>Using zinc finger nuclease technology to generate reporter-labelled human pluripotent stem cells as a tool to optimize photoreceptor transplantation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/I02333X/1</gtr:grantReference><gtr:abstractText>Pluripotent stem cells are unspecialized cells that can be grown in the laboratory and programmed to become specialized cells of a desired type, such as blood cells, muscle cells etc. Human pluripotent stem cells can be derived in different ways, from very early embryos when they become available as surplus products during in vitro fertilization, or more generally by re-programming easily accessible cells from individuals, such as from a sample of skin cells. This possibility has led to great interest in using stem cells for therapeutic applications to treat disorders caused by loss of cells of a particular type. For example, blindness due to loss of retinal cells could in principle be treated by taking a sample of skin cells from the patient, re-programme the skin cells to make unspecialized pluripotent stem cells and then programme the resulting stem cells to give retinal cell progenitors that can be grafted into the patient's eye to give rise to retinal cells. One of the difficult problems in differentiating human pluripotent stem cells is to track the cells as they change into specialized cells and then to purify the desired specialized cells. This can be done relatively easily for mouse pluripotent stem cells by inserting genes that make reporter molecules tagged with a fluorescent that makes the cells glow under suitable conditions, but the method is very inefficient in human pluripotent stem cells. A new cutting edge technology now offers a potential solution. Zinc finger nucleases are artificially created scissors that can be designed to specifically cut both strands of DNA molecules at just one specific location. These nucleases create a gap in the DNA structure which activates the cell's response for DNA repair. Upon presence of a short DNA stretch which shows similarity to the region containing the excision but also harbouring the reporter gene, it is possible to introduce the reporter gene into the gene of interest in human pluripotent stem cells. This technology is very recent and has only been applied twice in human pluripotent stem cells; however the efficiency has been much higher than other reported methods and as such the potential applications are immense. In this proposal we seek to implement this technology to create labelled human pluripotent stem cells lines that will be used as tools to optimise cell transplantation into the degenerate retina. The retina has a very complex structure consisting of several layers of neurons that are interconnected with each other. The two main cell types that are directly sensitive to light are the rod and cone photoreceptors cells. Our group has shown that it is possible to produce human cells that have the characteristics of cones and rods from human pluripotent stem cells. Despite this progress, we are not able to select these cells amongst other cell types that arise during differentiation process. Normally cell selection is achieved using a technique called fluorescence activated cell sorting (FACS). The different cells of the body have specific proteins on their surface to which antibodies tagged with coloured or fluorescent molecules can bind, allowing us to identify and sort them using FACS, however, there are few such markers that can be used for isolating cones and rods. We intend to introduce a reporter into an important retinal gene that marks their differentiation to cone and rods. The presence of the fluorescent reporter will allow us to use the cell selection strategy mentioned above to purify these cells. We can then ask the question of whether these cells exhibit the properties associated with rods and cones using a variety of in vitro stem cell assays and electrophysiological analysis. If successful, this approach will allow us to prospectively isolate rod and cone cells, define their molecular phenotype and test their ability to restore vision in animal models of retinal disease.</gtr:abstractText><gtr:technicalSummary>Blindness arising from outer retinal degeneration affects 314 million people worldwide. To date there are no effective treatments that can reverse the primary pathological abnormalities of retinal degeneration. For these reasons there is an emerging need for research into the replacement and/or reactivation of dysfunctional photoreceptors. New photoreceptors only make single synaptic connections to the inner retina, thus retinal repair by cell transplantation is a feasible approach. The only cells that have been shown to integrate successfully into host retina and restore vision are retinal cells that are already committed towards a photoreceptor fate. An equivalent human donor cell would have to be obtained from the second trimester embryo which raises ethical concerns and hence attention has been focused on differentiation of human pluripotent stem cells. Work carried out by our group and others has shown that it is possible to direct human pluripotent stem cell differentiation to cells that express photoreceptor markers in vitro, however their integration into the compromised retina in vivo is poor. This raises the question of whether the transplanted cells have matured to the correct ontogenetic stage that is needed for an efficient integration. To address this question we propose to use zinc finger nucleases to construct labelled human pluripotent stem cell lines in which a reporter gene is introduced into the endogenous loci of a key retinal transcription factor CRX shown to be expressed in postmitotic photoreceptor precursors and vital for their cell fate determination. This approach would enable isolation of photoreceptor precursors from human pluripotent stem cells, testing of their transplantation potential and full characterisation of their transcription profile with the aim of identifying cell surface markers that can be used for their easy isolation prior to transplantation.</gtr:technicalSummary><gtr:potentialImpactText>Blindness is often assumed to be avoidable or reversible with modern medicine, however many causes of blindness remain untreatable. Severe visual loss has a very significant impact on quality of life leading to social isolation and depression. Perhaps surprisingly the impact of significant visual impairment on an individual's quality of life is similar to that encountered with such devastating diseases as catastrophic stroke and cancer. Two of the most prevalent causes of blindness, namely age related macular degeneration (AMD) and hereditary retinal dystrophies (HRD), share a final common pathway of irreversible visual loss resulting from outer retinal degeneration with photoreceptor loss. AMD in particular is the most common cause of blindness in the western world. It is estimated to currently affect over 400,000 people in the UK and 8 million worldwide with a predicted increasing prevalence as the population ages and developing countries adopt the western lifestyle and diet. Although treatments are evolving for early AMD there is currently no cure, and treatments are largely palliative. Unfortunately clinical experience shows that patients are frequently seen with advanced disease, impaired vision and established outer retinal degeneration. HRD, although less prevalent, have a high health impact often causing profound visual loss from an early age. Until treatments are found that can reverse the primary pathological abnormalities in AMD and HRD, there is a need for research into the reactivation and replacement of non-functioning and lost cells within compromised outer retinal circuitry, whilst, critically, the inner retina is still intact. Transplantation of retinal progenitor cells into the eyes of such patients is a plausible and achievable treatment. Substantial evidence suggests that if such cells can be isolated and differentiated to the optimum stage for integration into the retina, then transplantation could result in the restoration of visual function. Quite apart from the obvious benefit to the patient, the ability to restore sight in these patients would have enormous social and economic benefits following the cessation of their long term palliative care. Indeed AMD is not only a major public health problem that has a devastating effect upon patients; it also has marked adverse financial consequences for the economy. An economic analysis based upon losses to gross domestic product in the USA suggests that AMD alone has an approximate $30 billion annual negative impact. The return on investment is therefore potentially high for the research costs invested in the development of new treatment modalities.</gtr:potentialImpactText><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>119572</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roche</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Hoffmann-La Roche</gtr:department><gtr:description>Roche collaboration</gtr:description><gtr:id>E54C202B-769D-4ADE-A9F9-ADE0876E79EA</gtr:id><gtr:piContribution>We are setting up collaboration with Roche pharmauceticals on pluripotent stem cell differentiation and genetic manipulation</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Institute for Cell Engineering Stem Cell Program</gtr:department><gtr:description>ZFN for retinal differentiation</gtr:description><gtr:id>EF0F653F-BF1E-4CEE-9F07-7716B9557A23</gtr:id><gtr:impact>one joint manuscript in preparation</gtr:impact><gtr:partnerContribution>Dr Linzhao Cheng's group at John Hopkins University (Baltimore, USA) has helped us to establish the Zinc finger nuclease (ZFN) technology in our laboratory.</gtr:partnerContribution><gtr:piContribution>Our aims are to use ZFN to establish reporter marked pluripotent stem cell lines for identifying optimal stages of photoreceptor emergence (for example CRX and NRL-GFP labelled cell lines) and correcting inherited mutations in patient specific pluripotent cell lines (for example RP1 patients).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Ophthalmology UCL</gtr:department><gtr:description>collaboration with Prof. Robin Ali</gtr:description><gtr:id>C2FCF3AC-6782-4116-9C74-67340C1455CC</gtr:id><gtr:impact>succesful award from Fight for Sight UK (two year project grant)</gtr:impact><gtr:partnerContribution>provision of skils, murine models and transplantation techniques</gtr:partnerContribution><gtr:piContribution>Our research groups are testing in collaboration the engraftment of hESC/hiPSC derived photoreceptor precursors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>stem cell festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>22B12239-335E-47DC-92E4-7D87979FCC9A</gtr:id><gtr:impact>about 300 members of the public attended the event

we have been asked to participate every year</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New tools for treating human inherited diseases</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E52FE301-2776-4DEF-81B9-DEB6AA594520</gtr:id><gtr:impact>Invited speaker: LivES symposium: Embryonic Stem Cells: Paris, 12-13th March 2012

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Putting a finger on stem cell biology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6E93A1A0-1B9F-4878-B32B-2FF3F2766BB4</gtr:id><gtr:impact>Invited Speaker at the EURETINA meeting, Rome, January 2012 Invited talk to the annual EURETINA meeting which brings together clinicians, researchers and policy makers from EU countries.

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited panellist of the European Opthalmology Futures Forum, London</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2657F73D-E312-4666-8EA4-1C2BD0D9FE9A</gtr:id><gtr:impact>Opthalmologists from clinical and academic areas get together in this forum to learn the most recent achievements in disease understanding and drug discovery

press release plus publication</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presenting scientist at the Northern Alliance RP Meeting, Newcastle</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>68F771A4-9621-4435-9A60-B32C6AC9B74F</gtr:id><gtr:impact>This is a regular event (2-3 times per year) in which Lako's group contributes regularly and serves to inform patients on recent progress made on treatment of retinal blindness as well as bringing the research group closer to patient needs.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Efficient stage specific differentiation of human pluripotent stem cells to photoreceptor progenitors</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2EB5C1D2-9D41-4C34-B29F-39518228946B</gtr:id><gtr:impact>Invited lecture at EURETINA meeting, 29th January 2012, Rome, Italy Prof. Lako gave a 30 minute lecture on the retinal differentiation from human pluripotent stem cells where BBSRC funding and project topic was recognised. 30 minute lecture

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stem Cells for treatment of blindness:Invited speaker at the Medica meeting Dusseldorf</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AB888EAC-CA1B-4BE9-B675-3789EEF4A956</gtr:id><gtr:impact>More than 500 health professionals attended this session

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Using stem cells to understand our development and human disease</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF9EF2F1-E974-4144-BCB2-02F7EB78AC89</gtr:id><gtr:impact>Talk

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seeing through stem cells</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CAF8437B-700B-4995-8CFE-879E4156093E</gtr:id><gtr:impact>Invited speaker and co-chair of &amp;quot;pluripotent stem cell differentiation session&amp;quot; at the UK-ISRAEL BIRAX conference organised by the British Council in Haifa, March 2014 Abstract for published conference book

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2 articles for reader digest published by the Macular Disease Society</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>83BABE02-CD9F-4154-AC8D-DEC093F5A75D</gtr:id><gtr:impact>Prof. Lako and Dr. Hallam described in two reader digest articles (respectively 2013 and 2014) the impact of their work on retinal disease understanding and modelling.

we have been asked to participate again for 2015</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presenting scientists at the Northern Alliance RP Meeting, Newcastle, 16th April 2016.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DF2A141B-E002-471B-B609-2D8A326BF977</gtr:id><gtr:impact>around 50 patients attended the event, asked questions and reinvited our team to attend the next local gathering.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Organiser of  the Newcastle RP Patient Information Day, 8th June 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E3E6AF07-61A1-49DC-BFC5-D19AC5E387C5</gtr:id><gtr:impact>98 patients and their families attended the event which sparked a lot of questions, discussion and increased interest in application of stem cell therapies for retinal disease.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://campus.recap.ncl.ac.uk/Panopto/Pages/Viewer.aspx?id=d7b01a8a-3dfe-486e-b0ae-bc8d02b3e3f9</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>inaugural meeting of Stem Cell Therapy Interest Group, Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>16850226-6C19-4D68-B6DE-A8BCE39FCE5F</gtr:id><gtr:impact>Lako: keynote speaker

This was an excellent event bringing together stem cell biologists from Glasgow and surrounding regions and great opportunity for networking.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at the RPFB patient day, 2014, Birmingham</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3C282663-261C-48B2-8DEB-6C2BB863024C</gtr:id><gtr:impact>more than 200 patients and their families attended the event.

We got amazing feedback from patients, how much they enjoyed the talks and how much they learnt on the recent scientific developments in the field.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presenting scientist at the Northern Alliance RP meeting, Newcastle, 19th November 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FD6D4350-945A-47A3-815E-B63E2581B23F</gtr:id><gtr:impact>50 patients and their families attended the event.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.retinalstemcellresearch.co.uk</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at the annual research day organised by RP Fighting Blindness UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9A20CF30-2008-4EF4-8694-FAEE19D91FF3</gtr:id><gtr:impact>more than 200 RP patients and their families attended the events as well as health professionals and researchers working in this area

we were asked to participate in the 2014 patient day event organised by RPFB</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at the annual research day organised by Macular Disease society UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7B00E3E6-E228-44AC-8995-E76CCDD7FD5A</gtr:id><gtr:impact>Around 80 patients and their families attended this event. Prof. Lako and Dr. Collin delivered two talks on the impact of stem cell developments and technologies on disease modelling and understanding.

We have been asked to participate in the next's year annual event.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker at the MipTec 2014 - The Leading European Event for Drug Discovery</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>76CF8832-808C-4804-B7AD-951B1F6EF1D3</gtr:id><gtr:impact>More than 500 industrial research participants attend this conference every year.

A collaborative research project with ROCHE is being developed following the talk at this conference.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote speaker at 13th British SCEV</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EAF6AF26-B86C-4E0D-8AE6-10ABF82D06F0</gtr:id><gtr:impact>Around 100 eye clinicians attended this meeting which discussed the recent progress on stem cell and gene therapy.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Insulin growth factor 1 is able to orchestrate formation of primitive ocular structures and stratified neural retina from human pluripotent stem cells</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E9D9BD91-6345-4AE5-93D2-BD6A9FC1094B</gtr:id><gtr:impact>plenary lecture lecture at Southampton Medical School

no actual impacts realised to date</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Stem cells for biological assays of novel drugs and predictive toxicology</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:fundingRef>STEMBANCC</gtr:fundingRef><gtr:id>6DBCA04A-1709-472A-926C-2F2B138800C3</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>62000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>Demonstrating proof of principle for generating a platform technology to direct differentiation of pluripotent stem cell using Sendai Viral vectors</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>ACE528A3-0DE3-4E21-B5E3-DD786F1FCA01</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>Spain, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sabbatical fellowship/Conselleria de Sanidad (Generalitat Valenciana), and the Instituto de Salud Carlos III (Ministry of Science and</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Spanish Ministry of Science and Innovation</gtr:fundingOrg><gtr:id>88505FA9-F661-4582-B24E-DAF8856175E2</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RP Fighting Blindness project grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>RP Fighting Blindness</gtr:fundingOrg><gtr:fundingRef>GR584</gtr:fundingRef><gtr:id>DC1E9414-F9BB-47B3-A3A2-54786A0CB449</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>41400</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NOVARTIS PROJECT GRANT</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>0606EE89-CF7C-4B14-BBD6-EAA6DF648B52</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>232500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>European Bank of induced pluripotent stem cells (EbiSC)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:fundingRef>EbiSC</gtr:fundingRef><gtr:id>1637662A-7A77-46F8-97AF-760DCA72F6AB</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Single Cell Genomics Unit</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M008886/1</gtr:fundingRef><gtr:id>D49382B6-AFC6-490C-BD1E-37C2D6DBC586</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>166000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fight for Sight UK project grant</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>9F3B1BEA-DD7C-433B-B599-11B1361BEEBB</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>625000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/BBSRC Human iPS cell research project grant</gtr:description><gtr:end>2009-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D93D6938-D917-4AD1-A165-2A38C82744B3</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC CONSOLIDATOR FELLOWSHIP</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>614620</gtr:fundingRef><gtr:id>51C864CA-0C96-4FF2-ACE1-FA74FA5B3FBD</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Integrated Mres/PhD studentship</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9920F03B-92C0-4129-AAE8-480BB3B20024</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The purpose of this study was to generate human embryonic stem cell (hESC) lines harbouring the green fluorescent protein (GFP) reporter at the endogenous loci of the Cone-Rod Homeobox (CRX) gene, a key transcription factor in retinal development. ZFNs designed to cleave in the 3' UTR of CRX were transfected into hESCs along with a donor construct containing homology to the target region, eGFP reporter and a puromycin selection cassette. Following selection, PCR and sequencing analysis of antibiotic resistant clones indicated targeted integration of the reporter cassette at the 3' of the CRX gene, generating a CRX-GFP fusion. Further analysis of a clone exhibiting homozygote integration of the GFP reporter was conducted suggesting genomic stability was preserved and no other copies of the targeting cassette were inserted elsewhere within the genome. This clone was selected for differentiation towards the retinal lineage. Immunocytochemistry of sections obtained from embryoid bodies and quantitative RT-PCR of GFP positive and negative subpopulations purified by fluorescence activated cell sorting during the differentiation indicated a significant correlation between GFP and endogenous CRX expression. Furthermore, GFP expression was found in photoreceptor precursors emerging during hESC differentiation, but not in the retinal pigmented epithelium (RPE), retinal ganglion cells or neurons of the developing inner nuclear layer. Together our data demonstrate the successful application of ZFN technology to generate CRX-GFP labelled hESC lines, which can be used to study and isolate photoreceptor precursors during hESC differentiation.</gtr:description><gtr:exploitationPathways>The CRX-GFP human ESC line is an extremely important tool for monitoring and improving pluripotent stem cell differentiation protocols to retinal lineages. Since the manuscript has been published we have received more than ten requests to distribute the line which we are doing using a MTA.</gtr:exploitationPathways><gtr:id>E49938F2-DBA2-40EE-A346-9B0A16D63797</gtr:id><gtr:sectors><gtr:sector>Education,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The co-applicant of these proposals (Mr. David steel) has performed RPE transplantation in patients with Stargardt's disease as part of the multi centre ACT trial.</gtr:description><gtr:id>29736264-0DDD-4226-944E-2F7AC6B4164F</gtr:id><gtr:impact>This is a phase I trial assessing the safety of hESC derived RPE cell transplantation into patients with severe retinal degeneration. Although the final data from this phase have not been published as yet, promising clinical results from a limited number of patients suggest that a phase II/III trial is very likely to go ahead and our centre is one of the partners involved in funding and liasons with regulatory bodies.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ACT clinical trial</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:ukcrnIsctnId>NCT01345006</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>a donor construct was made to introduce GFP into the endogenous CRX locus</gtr:description><gtr:id>EB1545CF-FBEB-45E6-BB40-934D011A8556</gtr:id><gtr:impact>this will enable other researchers to introduce this reporter into their human ESC and iPSC lines and monitor differentiation process</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>donor contructs for introducing GFP reporter into the 3' UTR of CRX gene</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FF17B03D-C8D5-4CF8-925E-2A016756CDAA"><gtr:id>FF17B03D-C8D5-4CF8-925E-2A016756CDAA</gtr:id><gtr:title>Efficient stage-specific differentiation of human pluripotent stem cells toward retinal photoreceptor cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1f9ae12417e7085ab2d1c329a907993"><gtr:id>b1f9ae12417e7085ab2d1c329a907993</gtr:id><gtr:otherNames>Mellough CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F977CB0-FBB3-47FA-9A8F-735C1EB2B412"><gtr:id>5F977CB0-FBB3-47FA-9A8F-735C1EB2B412</gtr:id><gtr:title>Using Zinc Finger Nuclease Technology to Generate CRX-Reporter Human Embryonic Stem Cells as a Tool to Identify and Study the Emergence of Photoreceptors Precursors During Pluripotent Stem Cell Differentiation.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52f57e90923c8c783ce1b858d944c58e"><gtr:id>52f57e90923c8c783ce1b858d944c58e</gtr:id><gtr:otherNames>Collin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38829F9D-9DCE-4A46-B202-C429262AEEE1"><gtr:id>38829F9D-9DCE-4A46-B202-C429262AEEE1</gtr:id><gtr:title>Lab generated retina: realizing the dream.</gtr:title><gtr:parentPublicationTitle>Visual neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1f9ae12417e7085ab2d1c329a907993"><gtr:id>b1f9ae12417e7085ab2d1c329a907993</gtr:id><gtr:otherNames>Mellough CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0952-5238</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/885B95E9-5819-4B97-8EEA-B52C68E6F899"><gtr:id>885B95E9-5819-4B97-8EEA-B52C68E6F899</gtr:id><gtr:title>IGF-1 Signaling Plays an Important Role in the Formation of Three-Dimensional Laminated Neural Retina and Other Ocular Structures From Human Embryonic Stem Cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1f9ae12417e7085ab2d1c329a907993"><gtr:id>b1f9ae12417e7085ab2d1c329a907993</gtr:id><gtr:otherNames>Mellough CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/371D7087-F90C-46F1-BADC-03D1FEC2760C"><gtr:id>371D7087-F90C-46F1-BADC-03D1FEC2760C</gtr:id><gtr:title>3D culture of human pluripotent stem cells in RGD-alginate hydrogel improves retinal tissue development.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/681fd0801fd1de7e49ac0cff1382adbc"><gtr:id>681fd0801fd1de7e49ac0cff1382adbc</gtr:id><gtr:otherNames>Hunt NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41E73B75-E977-40A0-8CB2-573A312FC333"><gtr:id>41E73B75-E977-40A0-8CB2-573A312FC333</gtr:id><gtr:title>Neural stem cells, a step closer to clinic?</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d61a61b7d2ee0407b73f296130f13efa"><gtr:id>d61a61b7d2ee0407b73f296130f13efa</gtr:id><gtr:otherNames>Stojkovic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8AC2F7AC-D120-4640-8844-5EA80092541E"><gtr:id>8AC2F7AC-D120-4640-8844-5EA80092541E</gtr:id><gtr:title>Editorial: Our top 10 developments in stem cell biology over the last 30 years.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35327529ca4f1df9cff05f5b7d814159"><gtr:id>35327529ca4f1df9cff05f5b7d814159</gtr:id><gtr:otherNames>Armstrong L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AE19EE27-FACD-44C7-A5A9-FBD264B38DA7"><gtr:id>AE19EE27-FACD-44C7-A5A9-FBD264B38DA7</gtr:id><gtr:title>Tissue engineering using pluripotent stem cells: multidisciplinary approaches to accelerate bench-to-bedside transition.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/681fd0801fd1de7e49ac0cff1382adbc"><gtr:id>681fd0801fd1de7e49ac0cff1382adbc</gtr:id><gtr:otherNames>Hunt NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/834AB932-9AD5-4AC5-A383-A275FA980D35"><gtr:id>834AB932-9AD5-4AC5-A383-A275FA980D35</gtr:id><gtr:title>Concise review: putting a finger on stem cell biology: zinc finger nuclease-driven targeted genetic editing in human pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52f57e90923c8c783ce1b858d944c58e"><gtr:id>52f57e90923c8c783ce1b858d944c58e</gtr:id><gtr:otherNames>Collin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1855A6F8-982E-4C38-8520-ABA62B30AADB"><gtr:id>1855A6F8-982E-4C38-8520-ABA62B30AADB</gtr:id><gtr:title>Induced pluripotent stem cells : it looks simple but can looks deceive?</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb15855be4efb413999bcd624a98656e"><gtr:id>cb15855be4efb413999bcd624a98656e</gtr:id><gtr:otherNames>Lako M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/I02333X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>